JP2014512808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512808A5 JP2014512808A5 JP2013556905A JP2013556905A JP2014512808A5 JP 2014512808 A5 JP2014512808 A5 JP 2014512808A5 JP 2013556905 A JP2013556905 A JP 2013556905A JP 2013556905 A JP2013556905 A JP 2013556905A JP 2014512808 A5 JP2014512808 A5 JP 2014512808A5
- Authority
- JP
- Japan
- Prior art keywords
- proteins
- disease
- transcription factor
- mammal
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 28
- 108090000623 proteins and genes Proteins 0.000 claims 28
- 102000004169 proteins and genes Human genes 0.000 claims 23
- 102000040945 Transcription factor Human genes 0.000 claims 14
- 108091023040 Transcription factor Proteins 0.000 claims 14
- 239000003446 ligand Substances 0.000 claims 14
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 239000002157 polynucleotide Substances 0.000 claims 13
- 241000124008 Mammalia Species 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 102000003951 Erythropoietin Human genes 0.000 claims 9
- 108090000394 Erythropoietin Proteins 0.000 claims 9
- 229940105423 erythropoietin Drugs 0.000 claims 9
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 9
- 230000001419 dependent effect Effects 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 7
- 208000002815 pulmonary hypertension Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 241000702421 Dependoparvovirus Species 0.000 claims 4
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 4
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 4
- 102000003996 Interferon-beta Human genes 0.000 claims 4
- 108090000467 Interferon-beta Proteins 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 4
- 229960001388 interferon-beta Drugs 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 206010019860 Hereditary angioedema Diseases 0.000 claims 3
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 102000011690 Adiponectin Human genes 0.000 claims 2
- 108010076365 Adiponectin Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 101710085045 B2 bradykinin receptor Proteins 0.000 claims 2
- 102400000967 Bradykinin Human genes 0.000 claims 2
- 101800004538 Bradykinin Proteins 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102000016267 Leptin Human genes 0.000 claims 2
- 108010092277 Leptin Proteins 0.000 claims 2
- 208000031964 Other metabolic disease Diseases 0.000 claims 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 229940076144 interleukin-10 Drugs 0.000 claims 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 2
- 229940039781 leptin Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010028774 Complement C1 Proteins 0.000 claims 1
- 102100025406 Complement C1s subcomponent Human genes 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 claims 1
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 229940127379 Kallikrein Inhibitors Drugs 0.000 claims 1
- 229940122920 Kallikrein inhibitor Drugs 0.000 claims 1
- 102100023012 Kallistatin Human genes 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 1
- 206010068690 Pulmonary vein occlusion Diseases 0.000 claims 1
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000007214 atherothrombosis Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 239000002329 esterase inhibitor Substances 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 238000005534 hematocrit Methods 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000018875 hypoxemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000005980 lung dysfunction Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 201000005665 thrombophilia Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449536P | 2011-03-04 | 2011-03-04 | |
| US61/449,536 | 2011-03-04 | ||
| US201161478881P | 2011-04-25 | 2011-04-25 | |
| US61/478,881 | 2011-04-25 | ||
| US201161490535P | 2011-05-26 | 2011-05-26 | |
| US61/490,535 | 2011-05-26 | ||
| US201161562342P | 2011-11-21 | 2011-11-21 | |
| US61/562,342 | 2011-11-21 | ||
| PCT/US2012/027515 WO2012122025A2 (en) | 2011-03-04 | 2012-03-02 | Vectors conditionally expressing protein |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017044305A Division JP2017141245A (ja) | 2011-03-04 | 2017-03-08 | タンパク質を条件的に発現するベクター |
| JP2017125428A Division JP2017212995A (ja) | 2011-03-04 | 2017-06-27 | タンパク質を条件的に発現するベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512808A JP2014512808A (ja) | 2014-05-29 |
| JP2014512808A5 true JP2014512808A5 (enExample) | 2015-04-16 |
| JP6189754B2 JP6189754B2 (ja) | 2017-08-30 |
Family
ID=46798719
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013556905A Expired - Fee Related JP6189754B2 (ja) | 2011-03-04 | 2012-03-02 | タンパク質を条件的に発現するベクター |
| JP2017044305A Withdrawn JP2017141245A (ja) | 2011-03-04 | 2017-03-08 | タンパク質を条件的に発現するベクター |
| JP2017125428A Withdrawn JP2017212995A (ja) | 2011-03-04 | 2017-06-27 | タンパク質を条件的に発現するベクター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017044305A Withdrawn JP2017141245A (ja) | 2011-03-04 | 2017-03-08 | タンパク質を条件的に発現するベクター |
| JP2017125428A Withdrawn JP2017212995A (ja) | 2011-03-04 | 2017-06-27 | タンパク質を条件的に発現するベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9402919B2 (enExample) |
| EP (2) | EP3450568A3 (enExample) |
| JP (3) | JP6189754B2 (enExample) |
| CN (1) | CN103534355A (enExample) |
| AU (1) | AU2012225749B2 (enExample) |
| CA (1) | CA2828411A1 (enExample) |
| SG (2) | SG192856A1 (enExample) |
| TW (1) | TWI582108B (enExample) |
| WO (1) | WO2012122025A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013158871A1 (en) * | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
| PL3133923T3 (pl) * | 2014-04-24 | 2021-02-22 | University Of Florida Research Foundation, Inc. | Oparta na aav genowa terapia stwardnienia rozsianego |
| JP6983511B2 (ja) * | 2014-04-25 | 2021-12-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脳中の転移乳癌および他の癌を処置するための方法および組成物 |
| ES2914081T3 (es) * | 2014-08-26 | 2022-06-07 | Hsf Pharmaceuticals | Agentes de inmunización y métodos de uso novedosos |
| JP6383621B2 (ja) * | 2014-09-24 | 2018-08-29 | 太陽インキ製造株式会社 | 硬化性組成物、ドライフィルム、硬化物、プリント配線板およびプリント配線板の製造方法 |
| SG10202012832VA (en) * | 2015-05-28 | 2021-01-28 | Univ Cornell | Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema |
| CN113999875A (zh) * | 2015-05-28 | 2022-02-01 | 康奈尔大学 | 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法 |
| WO2017062953A1 (en) | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| MX2018005886A (es) | 2015-11-11 | 2018-08-15 | Intrexon Corp | Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias. |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP3235516B1 (en) * | 2016-04-22 | 2019-06-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | Regulatable adeno-associated virus (aav) vector |
| EP3464586A4 (en) * | 2016-05-25 | 2019-11-20 | The Board of Trustees of the Leland Stanford Junior University | ACTIVITY-DEPENDENT EXPRESSION CONSTRUCTS AND METHODS FOR USE THEREOF |
| CN110191898B (zh) | 2016-06-08 | 2024-05-10 | 英特瑞克斯顿股份有限公司 | Cd33特异性嵌合抗原受体 |
| UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
| US11116852B2 (en) * | 2016-11-09 | 2021-09-14 | Precigen, Inc. | Frataxin expression constructs |
| WO2018132494A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| AU2018281316B2 (en) | 2017-06-07 | 2024-05-30 | Precigen, Inc. | Expression of novel cell tags |
| US20190256867A1 (en) | 2018-02-01 | 2019-08-22 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| EP3755795A4 (en) | 2018-02-19 | 2022-07-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| CN112088015A (zh) | 2018-03-06 | 2020-12-15 | 普莱西根股份有限公司 | 人乳头瘤病毒疫苗及其用途 |
| CA3103372A1 (en) * | 2018-06-27 | 2020-01-02 | Precigen, Inc. | In vivo controlled combination therapy for treatment of cancer |
| SG11202100205UA (en) * | 2018-07-10 | 2021-02-25 | Precigen Inc | Ror-1 specific chimeric antigen receptors and uses thereof |
| CN113454459A (zh) * | 2019-02-18 | 2021-09-28 | 利物浦大学 | 诊断方法 |
| AU2020236937B2 (en) | 2019-03-08 | 2023-06-15 | Obsidian Therapeutics, Inc. | CD40L compositions and methods for tunable regulation |
| WO2020206056A1 (en) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides and methods of plant protection |
| JP2023509770A (ja) | 2020-01-08 | 2023-03-09 | オブシディアン セラピューティクス， インコーポレイテッド | 転写の調節可能な制御のための組成物及び方法 |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| WO2021211640A1 (en) * | 2020-04-14 | 2021-10-21 | University Of Florida Research Foundation, Incorporated | Enhanced effects of gene-immunotherapy and immunosuppressants in multiple sclerosis |
| WO2021211614A1 (en) | 2020-04-14 | 2021-10-21 | University Of Florida Research Foundation, Incorporated | Aav-based gene therapies for treatment of autoimmune diseases |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| CN112741895A (zh) * | 2021-01-19 | 2021-05-04 | 中国人民解放军陆军军医大学 | Epo类似物在制备治疗脓毒症药物中的应用 |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3360004A (en) | 1965-09-07 | 1967-12-26 | Bendix Corp | Pressure proportioning valve |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
| FR2593630B1 (fr) | 1986-01-27 | 1988-03-18 | Maurice Francois | Ecran d'affichage a matrice active a resistance de drain et procedes de fabrication de cet ecran |
| US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
| US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| CA2043775A1 (en) | 1990-06-14 | 1991-12-15 | Dat P. Le | Dibenzoylakylcyanohydrazines |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
| IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
| US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
| CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US20020107211A1 (en) * | 1995-06-07 | 2002-08-08 | The Rockefeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5962311A (en) | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| ATE293699T1 (de) | 1995-03-03 | 2005-05-15 | Syngenta Participations Ag | Kontrolle der pflanzengenexpression durch rezeptor-vermittelte transaktivation in gegenwart von einem chemischen ligand |
| WO1996037609A1 (en) | 1995-05-26 | 1996-11-28 | Zeneca Limited | A gene switch comprising an ecdysone receptor |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| CA2269654A1 (en) * | 1996-08-23 | 1998-02-26 | Arch Development Corporation | Long-term expression of gene products by transforming muscle cells |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| AU8067698A (en) | 1997-06-09 | 1998-12-30 | Genvec, Inc. | Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus |
| US20100190692A1 (en) | 1997-07-04 | 2010-07-29 | Van Groeninghen Johannes C | Methods for reducing gnrh-positive tumor cell proliferation |
| AU3659497A (en) * | 1997-07-11 | 1999-02-08 | Canji, Inc. | Organ-specific targeting of cationic amphiphile/retinobl astoma encoding dna complexes for gene therapy |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| US6479653B1 (en) | 1997-08-26 | 2002-11-12 | Ariad Gene Therapeutics, Inc. | Compositions and method for regulation of transcription |
| US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| AU9036198A (en) | 1997-08-26 | 1999-03-16 | Ariad Gene Therapeutics, Inc. | Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
| US20020048792A1 (en) | 1997-08-26 | 2002-04-25 | Ariad Gene Therapeutics, Inc. | Methods and materials for regulated production of proteins |
| CA2304173A1 (en) | 1997-09-23 | 1999-04-01 | Genvec, Inc. | Plasmids for construction of eukaryotic viral vectors |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| CA2328462C (en) | 1998-04-22 | 2010-11-09 | Genvec, Inc. | Efficient purification of adenovirus |
| US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US6258603B1 (en) | 1998-06-17 | 2001-07-10 | Rohm And Haas Company | Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| DE19831420A1 (de) * | 1998-07-14 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren |
| US5965358A (en) | 1998-08-26 | 1999-10-12 | Genvec, Inc. | Method for assessing the relative purity of viral gene transfer vector stocks |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
| US7410941B1 (en) | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
| US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US6831060B2 (en) * | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| AU754770B2 (en) | 1999-05-17 | 2002-11-21 | Conjuchem Biotechnologies Inc. | Long lasting insulinotropic peptides |
| US6225895B1 (en) | 1999-05-26 | 2001-05-01 | Floyd E. Bigelow, Jr. | Towed vehicle monitor system |
| WO2001003722A1 (en) * | 1999-07-09 | 2001-01-18 | Mayo Foundation For Medical Education And Research | Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing |
| US20030186386A1 (en) * | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| CA2404253C (en) | 2000-03-22 | 2014-05-13 | Rohm And Haas Company | Novel ecdysone receptor-based inducible gene expression system |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US7531326B2 (en) | 2001-02-20 | 2009-05-12 | Intrexon Corporation | Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
| AU2002248500B2 (en) | 2001-02-20 | 2007-12-13 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| DK1373470T3 (da) | 2001-02-20 | 2013-07-29 | Intrexon Corp | Hidtil ukendte substitutionsmutantreceptorer og deres anvendelse i et cellekernereceptorbaseret inducerbart genekspressionssystem |
| AU2002247184B2 (en) | 2001-02-20 | 2008-06-19 | Intrexon Corporation | Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system |
| US20020168739A1 (en) * | 2001-03-09 | 2002-11-14 | Wu Kenneth K. | Vectors, compositions and methods for treating a vascular disorder |
| US20030091544A1 (en) * | 2001-03-13 | 2003-05-15 | Vical Incorporated | Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases |
| US7588758B2 (en) * | 2001-09-11 | 2009-09-15 | University Of Medicine And Dentistry Of New Jersey | COX-2 function and wound healing |
| US7563879B2 (en) | 2001-09-26 | 2009-07-21 | Intrexon Corporation | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| US7919269B2 (en) | 2001-09-26 | 2011-04-05 | Intrexon Corporation | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| US20060052292A1 (en) * | 2001-12-21 | 2006-03-09 | Maxygen Aps Maxygen Holdings, Ltd. | Adiponectin fragments and conjugates |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| US20050228016A1 (en) | 2002-06-13 | 2005-10-13 | Enrique Michelotti | Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US20040049437A1 (en) | 2002-09-11 | 2004-03-11 | Govone Solutions, Lp | Method, system and computer program product for automating transaction tax calculation |
| WO2004034971A2 (en) * | 2002-09-25 | 2004-04-29 | The Center For Blood Research, Inc. | Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| US7785871B2 (en) | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| US20080050808A1 (en) | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
| US6989369B2 (en) * | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
| US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| ES2447423T3 (es) | 2003-08-29 | 2014-03-12 | Dyax Corp. | Inhibidores de proteasa poli-pegilados |
| WO2005026457A1 (en) | 2003-09-15 | 2005-03-24 | Jeong Ho Yang | Removable attachement-type shower unit |
| EP1743676A1 (en) | 2003-11-12 | 2007-01-17 | Phenomix Corporation | Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors |
| US20050145385A1 (en) | 2004-01-05 | 2005-07-07 | Nguyen Philip D. | Methods of well stimulation and completion |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| AU2005248371B2 (en) | 2004-05-18 | 2011-12-15 | Intrexon Corporation | Methods for dynamic vector assembly of DNA cloning vector plasmids |
| WO2006017292A1 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Constrained cyano compounds |
| US20060027071A1 (en) | 2004-08-06 | 2006-02-09 | Barnett Ronald J | Tensegrity musical structures |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| WO2006055973A2 (en) | 2004-11-22 | 2006-05-26 | University Of Utah Research Foundation | Erythropoietin for treatment of multi-organ failure |
| CA2590254A1 (en) | 2004-12-20 | 2006-06-29 | Wyeth | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders |
| AU2005319454B2 (en) | 2004-12-20 | 2012-08-09 | Wyeth | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
| US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
| KR20080000665A (ko) | 2005-04-22 | 2008-01-02 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 디펩티딜 펩티다아제-ⅳ 억제제 |
| JP2008546732A (ja) | 2005-06-23 | 2008-12-25 | アプラゲン ゲーエムベーハー | 多価化合物 |
| EP1967582A4 (en) | 2005-12-26 | 2009-04-15 | Kuraray Co | MATERIAL FOR THE CELL CULTURE |
| EP2001500A4 (en) | 2006-03-10 | 2010-07-28 | Dyax Corp | FORMULATIONS FOR ECALLANTIDE |
| WO2007136752A2 (en) * | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Erythropoietin compositions |
| PL2054074T3 (pl) * | 2006-08-04 | 2015-03-31 | Prolong Pharmaceuticals Llc | Zmodyfikowana erytropoetyna |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2676036A1 (en) | 2007-02-02 | 2008-08-14 | Amgen Inc. | Hepcidin, hepcidin antagonists and methods of use |
| EP1972349A1 (en) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
| TWI407960B (zh) * | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| BRPI0811348B1 (pt) | 2007-05-29 | 2022-02-08 | Intrexon Corporation | Composto, (n-(1-ter-butil-butil)-n'-(2-etil-3-metóxi benzoil)-hidrazida de ácido (r)-3,5-dimetilbenzóico e composição farmacêutica |
| WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
| EP2185730A4 (en) | 2007-08-23 | 2010-10-27 | Intrexon Corp | METHOD AND COMPOSITIONS FOR SICKNESS DIAGNOSIS |
| AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
| AU2008307643B9 (en) * | 2007-09-28 | 2014-04-17 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| MX2010003720A (es) * | 2007-10-08 | 2010-10-20 | Intrexon Corp | Celulas dendriticas creadas por ingenieria genetica y usos para el tratamiento de cancer. |
| EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
| RU2493828C2 (ru) | 2008-07-14 | 2013-09-27 | Отономи, Инк. | Модулирующие апоптоз композиции с контролируемым высвобождением и способы лечения заболеваний уха |
| DK2342223T3 (en) | 2008-09-26 | 2017-07-24 | Ambrx Inc | Modified animal erythropoietin polypeptides and their uses |
| KR101629071B1 (ko) * | 2008-10-08 | 2016-06-09 | 인트렉손 코포레이션 | 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도 |
| CN104922669A (zh) | 2008-11-13 | 2015-09-23 | 通用医疗公司 | 用于通过调整bmp-6来调节铁稳态的方法和组合物 |
| US8921329B2 (en) * | 2008-12-04 | 2014-12-30 | Curna, Inc. | Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO |
| WO2010129310A1 (en) | 2009-04-27 | 2010-11-11 | Roswell Park Cancer Institute | Reagents and methods for producing bioactive secreted peptides |
| EP3284821B1 (en) | 2010-03-23 | 2022-01-05 | Precigen, Inc. | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| EP2808057B1 (en) | 2013-05-31 | 2016-02-03 | RaySearch Laboratories AB | Method and system for robust radiotherapy treatment planning |
-
2012
- 2012-03-02 WO PCT/US2012/027515 patent/WO2012122025A2/en not_active Ceased
- 2012-03-02 US US14/001,943 patent/US9402919B2/en not_active Expired - Fee Related
- 2012-03-02 CA CA2828411A patent/CA2828411A1/en not_active Abandoned
- 2012-03-02 AU AU2012225749A patent/AU2012225749B2/en not_active Ceased
- 2012-03-02 EP EP18188076.6A patent/EP3450568A3/en not_active Withdrawn
- 2012-03-02 SG SG2013063045A patent/SG192856A1/en unknown
- 2012-03-02 JP JP2013556905A patent/JP6189754B2/ja not_active Expired - Fee Related
- 2012-03-02 CN CN201280021577.XA patent/CN103534355A/zh active Pending
- 2012-03-02 SG SG10201600912SA patent/SG10201600912SA/en unknown
- 2012-03-02 EP EP12755403.8A patent/EP2681327B1/en not_active Not-in-force
- 2012-03-03 TW TW101107160A patent/TWI582108B/zh not_active IP Right Cessation
-
2016
- 2016-05-11 US US15/151,947 patent/US20160317678A1/en not_active Abandoned
-
2017
- 2017-03-08 JP JP2017044305A patent/JP2017141245A/ja not_active Withdrawn
- 2017-06-27 JP JP2017125428A patent/JP2017212995A/ja not_active Withdrawn
-
2018
- 2018-05-31 US US15/993,773 patent/US20180344876A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512808A5 (enExample) | ||
| US12409236B2 (en) | Liver-specific nucleic acid regulatory elements and methods and use thereof | |
| Jozwiak et al. | Post-resuscitation shock: recent advances in pathophysiology and treatment | |
| JP2014526441A5 (enExample) | ||
| Evans et al. | Use of angiotensin II for post cardiopulmonary bypass vasoplegic syndrome | |
| EP3393523B1 (en) | Endothelium-specific nucleic acid regulatory elements and methods and use thereof | |
| JP2017538395A (ja) | 代謝障害を処置するための組成物及びその使用方法 | |
| JP2010202664A5 (enExample) | ||
| JP2019523648A5 (enExample) | ||
| JP2015509504A5 (enExample) | ||
| JP2016512205A5 (enExample) | ||
| KR20180021736A (ko) | 세포의 항아폽토시스, 생존, 또는 증식을 유도하기 위한 조성물 및 방법 | |
| Kappel et al. | Management of moyamoya disease: a review of current and future therapeutic strategies | |
| JP2004501650A5 (enExample) | ||
| WO2021016727A1 (zh) | 针对纤维化、炎症、和/或老化疾病的治疗药物 | |
| Cheng et al. | New insights into circRNA and its mechanisms in angiogenesis regulation in ischemic stroke: a biomarker and therapeutic target | |
| White et al. | Sildenafil prevents Marfan-associated emphysema and early pulmonary artery dilation in mice | |
| JP2015521611A5 (enExample) | ||
| JP2016508036A5 (enExample) | ||
| Bergt et al. | Toll-like receptor 4 deficiency or inhibition does not modulate survival and neurofunctional outcome in a murine model of cardiac arrest and resuscitation | |
| JP2014512369A5 (enExample) | ||
| Ding et al. | Genomic Editing of a Pathogenic Mutation in ACTA2 Rescues Multisystemic Smooth Muscle Dysfunction Syndrome in Mice | |
| Liu et al. | Research status and future perspectives of IL-27 in the treatment of stroke | |
| JP7616697B2 (ja) | ウイルス性肺炎を治療する方法及び薬剤 | |
| WO2018053143A1 (en) | Composition and method for inducing anti-apoptosis, survival, or proliferation of a cell |